The EU approvals committee has recommended Teva Pharmaceutical Industries Ltd.'s humanized interleukin-5 antagonist monoclonal antibody, Cinqaero (reslizumab), for use as an add-on therapy in adult patients with severe eosinophilic asthma, whose disease has been inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Teva Gets EU Green Light For Reslizumab
Teva is set to get its severe asthma treatment Cinqaero onto the EU market following a positive opinion from the CHMP but, as in the US, its label will restrict its use to adult patients.
More from New Products
More from Scrip
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.